About two weeks before the onset of the first-quarter 2021 earnings season for life science companies, there were two preannouncements in 24 hours. While neither company was a therapeutic drug company
Third-quarter device financing activity reached $3.3bn, a significant drop from Q2’s $9.5bn, although 45% of the Q2 dollars can be attributed to two billion-dollar plus transactions: Stryker Corporat